Close Menu

NEW YORK (GenomeWeb) – Natera said this week that the US Food and Drug Administration has granted breakthrough device designation for its circulating tumor DNA test, which is currently available for research. The ctDNA test, Signatera, is a bespoke assay that analyzes a handful of mutations in a patient's tumor identified through tumor biopsy and sequencing. The FDA granted the designation for Signatera for use in patients previously diagnosed with certain cancer types and in combination with certain drugs.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The former commissioner of the FDA has returned to the venture capital firm New Enterprise Associates as a special partner on the healthcare investment team.

Astronauts have edited yeast genes on the International Space Station in an experiment designed to show how cells repair themselves in space.

Emory University has found that two of its researchers failed to divulge they had received funds from China, according to the Atlanta Journal-Constitution.

In Science this week: influence of the nuclear genome on human mitochondrial DNA, and more.